Patent Foramen Ovale Closure, Antiplatelet Therapy or Anticoagulation Therapy Alone for Management of Cryptogenic Stroke?
BMJ 362:k2515, Kuijpers, T.,et al, 2018
Prevention of Stroke in Patients with Silent Cerebrovascular Disease
Stroke 48:e44-e71, Smith, E.E.,et al, 2017
Controlled Trial of Transfusions for Silent Cerebral Infarcts in Sickle Cell Anemia
NEJM 371:699-710, DeBaun, M.R.,et al, 2014
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
NEJM 368:1092-1100,1152, Carroll, J.D.,et al, 2013
Percutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
NEJM 368:1083-1091,1152, Meier, B.,et al, 2013
Patent Foramen Ovale Closure and Medical Treatments for Secondary Stroke Prevention
Stroke 43:422-431, Kitsios,G.D.,et al, 2012
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
NEJM 366:991-999,1048, Furlan,A.J.,et al, 2012
Therapeutic Strategies After Examination by Transesophageal Echocardiography in 503 Patients with Ischemic Stroke
Stroke 37:859-864, Harloff,A.,et al, 2006
Clopidogrel for Reduction of Atherosclerotic Events
The Medical Letter 40:59-60, , 1998
Surgical Closure of Patent Foramen Ovale in Cryptogenic Stroke Patients
Stroke 28:2376-2381, Homma,S.,et al, 1997